How much funding has Reunion Neuroscience raised?

Reunion Neuroscience has raised $103.0M in total funding, most recently a Series A round.

Who are Reunion Neuroscience's investors?

Reunion Neuroscience's investors include Novo Holdings A/S, MPM BioImpact.

When was Reunion Neuroscience founded?

Reunion Neuroscience was founded in 2022.

Where is Reunion Neuroscience headquartered?

Reunion Neuroscience is headquartered in Toronto, Canada.

What industry is Reunion Neuroscience in?

Reunion Neuroscience operates in Biotech, Healthcare.

How many employees does Reunion Neuroscience have?

Reunion Neuroscience has 11-50 employees.

Reunion Neuroscience

Advancing psychedelic therapeutics for underserved mental health conditions

Toronto, Canada · Founded 2022 · $103.0M raised

Biotech

Healthcare

Headquarters: Toronto
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: reunionneuro.com
Total Funding: $103.0M
Last Round: $103.0M Series AMay 2024
Rounds: 1

About

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing patented serotonergic psychedelic therapeutics for underserved mental health disorders. The company's lead candidate, luvesilocin — the only 4-OH-DiPT prodrug in clinical development — is designed as a fast-acting, short-duration therapy and achieved its primary endpoint in the Phase 2 REKINDLE trial for postpartum depression (PPD), earning Breakthrough Therapy Designation from the FDA. Reunion is advancing luvesilocin into a pivotal Phase 3 trial for PPD in 2026, alongside Phase 2 studies in adjustment disorder and generalized anxiety disorder. The company was spun out of Field Trip Health Ltd. and is headquartered in Toronto, Canada.

Summary

Reunion Neuroscience is a Biotech company based in Toronto, Canada, founded in 2022. It has raised $103.0M in total across 1 round, most recently a $103.0M Series A round in May 2024. Investors include Novo Holdings A/S and MPM BioImpact.